SAN DIEGO, Oct. 30, 2012 (GLOBE NEWSWIRE) -- TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) expects to announce its Q3 2012 financial results before the market opens on Tuesday, November 13, 2012.
TearLab is pleased to invite all willing participants in a conference call during which time financial results will be discussed. This call will be held at 8:30am Eastern at 877-303-1593.
| Date: November 13, 2012 |
| Time: 8:30 AM ET |
| Listen via Internet: http://www.tearlab.com/investor/ |
| Schedule this webcast into MS-Outlook calendar (click open when prompted): |
| http://apps.shareholder.com/PNWOutlook/t.aspx?m=56297&k=79CDBDC0 |
| Telephone: 877-303-1593 |
For those wishing to listen to a recording of the call via telephone, a replay will be made available by 11:30am Eastern after the conclusion of the live call and will remain posted until 11:59 pm Eastern on November 19, 2012. To listen to the recording, simply telephone 855-859-2056 (toll free) or 404-537-3406 and enter conference ID: 60079371 when prompted.
About TearLab Corporation
TearLab Corporation (www.tearlab.com) develops and commercializes lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The TearLab(R) Osmolarity Test, that enables eye care practitioners to test for highly sensitive and specific biomarkers using nanoliters of tear film at the point-of-care, is the first assay developed for the award winning TearLab Osmolarity System. Headquartered in San Diego, CA, TearLab Corporation's common shares trade on the NASDAQ Capital Market under the symbol 'TEAR' and on the Toronto Stock Exchange under the symbol 'TLB'.
Forward-Looking Statements This press release may contain forward-looking statements. These statements relate to future events and are subject to risks, uncertainties and assumptions about TearLab. Examples of forward-looking statements in this press released include predictions regarding the sufficiency of current cash and cash equivalents to fund operations for 12 months or more, building sales in Europe and Canada and the future commercial adoption of the TearLab Osmolarity System. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. Many factors may cause our actual results to differ materially from any forward-looking statement, including the factors detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our annual and quarterly reports on Forms 10-K and 10-Q. We do not undertake to update any forward-looking statements.